Item 8.01 Other Events.

On July 2, 2021, Mirati Therapeutics, Inc. ("we," "Mirati" or the "Company") entered into an amended and restated sales agreement (the "Sales Agreement") with Cowen and Company, LLC ("Cowen"), pursuant to which the Company may, from time to time, sell shares of the Company's common stock, par value $0.001 per share (the "Shares"), having an aggregate offering price of up to $500,000,000 through or to Cowen, as the Company's agent and/or principal.

Subject to the terms and conditions of the Sales Agreement, Cowen will use its commercially reasonable efforts to sell the Shares from time to time, based upon the Company's instructions. The Company has provided Cowen with customary indemnification rights, and Cowen will be entitled to a commission of up to 3.0% of the gross sales price of the Shares sold through it pursuant to the Sales Agreement.

The Shares will be offered and sold by the Company pursuant to its shelf registration statement on Form S-3ASR (the "S-3 Registration Statement"), which became automatically effective upon filing with the Securities and Exchange Commission (the "SEC") on July 2, 2021. The Shares may be offered only by means of a prospectus, including a prospectus supplement, forming a part of the S-3 Registration Statement. Sales of the Shares, if any, under the Sales Agreement may be made in transactions that are deemed to be "at the market offerings" as defined in Rule 415 under the Securities Act of 1933, as amended, including sales made by means of ordinary brokers' transactions, including on The Nasdaq Global Select Market, at market prices or as otherwise agreed with Cowen. The Company has no obligation to sell any of the Shares, and may at any time suspend offers under the Sales Agreement or terminate the Sales Agreement.

The foregoing description of the Sales Agreement does not purport to be complete and is qualified in its entirety by reference to the full Sales Agreement, a copy of which is filed as Exhibit 1.2 to the S-3 Registration Statement.

This Current Report on Form 8-K does not constitute an offer to sell the Shares or a solicitation of an offer to buy the Shares, nor shall there be any sale of the Shares in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses